Rethinking access barriers to innovationMarket access issues don’t stop once a product has passed HTA – and this is especially true for Share XRethinking access barriers to innovationhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/rethinking-access-barriers-to-innovation/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
